CION Ameerpet
Blood Cancer & Transplant · GVHD Explained
Graft-Versus-Host Disease After Transplant — What It Is, and What It Is Not
Graft-versus-host disease (GVHD) is what happens when immune cells from a donor treat your body as foreign and attack it. It follows an allogeneic stem cell transplant — a transplant that uses another person’s cells. The skin, the gut and the liver are hit most often. Most people treated for lymphoma or another blood cancer in India will never face it, because most are not candidates for an allogeneic transplant in the first place. Allogeneic transplant and CAR-T are carried out at designated transplant centres, not at CION. This page exists because families are constantly told GVHD is “an immunotherapy side effect”. It is not, and this page sets out the difference.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Only after a donor transplant — GVHD needs someone else’s immune cells. It is not expected after an autologous (own-cell) transplant, and it is not a checkpoint-inhibitor side effect.
- Skin, gut and liver first — A spreading rash, watery diarrhoea and yellowing of the eyes are the classic early signs. Each one is reported to the transplant centre the same day.
- The early and long-lasting forms behave differently — Early GVHD comes on fast. The chronic form comes on slowly and affects eyes, mouth, skin, joints and lungs for years.
- Transplant and CAR-T are referred, not done here — CION does not perform allogeneic transplant and does not provide CAR-T or cell therapy. We refer to designated centres and stay in the follow-up.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What Is Graft-Versus-Host Disease?
Graft-versus-host disease is a reaction in which immune cells from a donor treat your body as foreign and attack it. It happens only after an allogeneic stem cell transplant, which uses cells from another person. The skin, the gut and the liver are affected most often. It is not an infection.
Who this page is actually for. Most people treated for lymphoma or another blood cancer in India will never have graft-versus-host disease, because most are not candidates for an allogeneic transplant. That option is offered to a small group, selected on disease type, remission status, age, general fitness, organ function and whether a suitable donor exists. We say that before describing anything else, because families arrive convinced a donor transplant is the obvious next step, and for most it is not.
Where it is done. Allogeneic stem cell transplant and CAR-T cell therapy are carried out at designated transplant centres. CION does not perform allogeneic transplant and does not provide CAR-T or any other cell therapy. Where those options are relevant, we refer, and we stay involved in the follow-up alongside the transplant centre.
| Form of GVHD | Typically starts | What it usually looks like |
|---|---|---|
| Early (acute pattern) | First few weeks to around three months after the transplant | Rash, watery diarrhoea, nausea, yellowing of the eyes or skin. Comes on quickly, sometimes over days. |
| Long-lasting (chronic pattern) | Usually from around three months onward, sometimes much later | Dry eyes, dry or sore mouth, tight or thickened skin, joint stiffness, breathlessness. Comes on slowly and can persist for years. |
| Overlap | Any time | Features of both patterns present together. Recognised as its own pattern and managed accordingly. |
The old rule that day 100 divides acute from chronic GVHD has been replaced. Transplant centres now classify it by what it looks like rather than by the calendar, following the NIH consensus criteria. If a report still uses the day-100 rule, ask which pattern is actually being described.
Did you know?
GVHD is the only major cancer-treatment complication driven by someone else’s immune cells rather than your own. That single difference is why it is graded, monitored and treated on a completely separate track from the immune-related side effects of checkpoint-inhibitor immunotherapy — and why the two should never be recorded in your file as the same thing.
Symptoms by organ
Which Organs Does Graft-Versus-Host Disease Affect?
Early graft-versus-host disease affects three organs above all: the skin, the gastrointestinal tract and the liver. The long-lasting form can involve many more, including the eyes, mouth, joints, genitals and lungs. Skin is usually the first to show it. Every symptom below is reported on the day it appears.
| Organ | What you might notice | Typically starts |
|---|---|---|
| Skin | A red rash, sometimes itchy or burning, often starting on the palms, soles, ears or upper back. It can spread over large areas. | Often the first sign, in the early weeks after transplant. |
| Gut — stomach and bowel | Watery diarrhoea, cramping, nausea, vomiting, loss of appetite, sometimes blood in the stool. | Early weeks to a few months. Can escalate quickly. |
| Liver | Yellowing of the eyes or skin, dark urine, pale stools. Often abnormal on blood tests before you feel unwell. | Early weeks to a few months; frequently picked up on bloods first. |
| Eyes | Persistent grittiness, dryness, light sensitivity, blurred vision. | Usually a long-lasting feature, from around three months onward. |
| Mouth | Dryness, soreness, white lace-like patches, pain with spicy or acidic food, difficulty opening the mouth fully. | Usually long-lasting, from around three months onward. |
| Skin, joints and connective tissue | Tight, thickened or discoloured skin. Reduced movement in fingers, wrists or shoulders. | Long-lasting form, months to years after transplant. |
| Lungs | New breathlessness climbing stairs, a dry cough that does not settle, falling exercise tolerance. | Long-lasting form, and usually gradual — which is why it gets missed. |
| Genitals | Dryness, soreness, narrowing or pain with intercourse. Rarely raised by patients unless asked directly. | Long-lasting form, from around three months onward. |
Contact the transplant centre the same day if any of these appear: watery diarrhoea more than a few times a day, blood in the stool, a rash spreading across large areas of the body, yellowing of the eyes, or new breathlessness. Do not wait for the next scheduled review, and do not treat bowel symptoms at home as ordinary loose motion.
If you cannot reach the transplant centre and symptoms are worsening, go to the nearest emergency department now. If you are in Telangana or Andhra Pradesh and need help reaching the right team, our helpline is 1800 202 8726.
The confusion this page exists to fix
Is GVHD the Same as an Immunotherapy Side Effect?
No. They are different conditions with different causes. GVHD is caused by a donor’s immune cells attacking your tissues after an allogeneic transplant. An immune-related side effect is caused by your own immune cells, released from their brakes by a checkpoint-inhibitor drug. The symptoms overlap. The cause, the setting and the team do not.
| Graft-versus-host disease | Immune-related side effect of checkpoint-inhibitor immunotherapy | |
|---|---|---|
| Whose immune cells | The donor’s | Your own |
| What triggers it | An allogeneic stem cell transplant using another person’s cells | A checkpoint-inhibitor infusion given for a cancer such as lung, kidney, head and neck or oral cancer |
| Can it happen without a donor transplant? | No | Yes — no transplant is involved at all |
| Organs most often affected | Skin, gut, liver; later eyes, mouth, joints, lungs | Skin, gut, thyroid, liver; less often lungs, heart, adrenal glands |
| Typical timing | Weeks to months after the transplant; the long-lasting form runs for months to years | Any time from the first cycle to months after the last one |
| Who leads the care | The transplant centre that performed the graft | Your medical oncologist |
| Where it is treated | A designated transplant centre | The immunotherapy itself is given as day care at CION centres |
Why this matters more than it sounds. The two are managed by different teams, on different monitoring schedules. A discharge summary that records a donor-transplant complication as an “immunotherapy side effect”, or the reverse, sends the next doctor who reads it down the wrong path. If your paperwork uses one term while your treatment history points to the other, ask for it to be corrected in writing.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Understand the Plan Before You Agree to It
A 45-minute consultation with your reports in front of us, a tumour board review, and a written plan with clear costs. No rushed decisions.
Management
How Is Graft-Versus-Host Disease Managed?
Management has three parts: prevention around the transplant, early recognition of symptoms, and treatment that suppresses the donor immune reaction. Limited skin disease may be treated locally. More extensive disease is treated with steroids, with further immune-suppressing medicines added if steroids are not enough. All of it is directed by the transplant centre.
- 1
Prevention starts before the graft, not after symptoms
The donor is matched as closely as possible, and preventive immune-suppressing medicines are started around the time of the transplant. This is planned by the transplant centre in advance. Nothing about it is decided once a rash has already appeared.
- 2
You are taught what to watch for, and you report it the same day
Rash, diarrhoea, jaundice, and mouth or eye changes are reported on the day they appear rather than saved for the next visit. Early GVHD is far easier to control than established GVHD. This is the one part of the process that depends entirely on you.
- 3
It is confirmed and graded, not assumed
The transplant team examines you, checks blood tests, and often takes a small biopsy of skin, bowel or liver to confirm GVHD rather than treat on suspicion. Severity is graded organ by organ using the criteria transplant centres follow, and that grade decides the treatment.
- 4
Treatment suppresses the donor immune reaction
Limited skin-only disease may be treated with topical treatment alone. More extensive disease is treated with steroids. If it does not respond, further immune-suppressing options are added. The aim is to bring the reaction under control with the lowest exposure that works, because these medicines carry their own risks.
- 5
Infection cover and long-term follow-up run alongside
Suppressing the immune system raises infection risk, so preventive anti-infective cover, a rebuilt vaccination schedule and regular review continue for as long as treatment does. The long-lasting form is followed for years. Where travel is difficult, we coordinate that follow-up locally with the transplant centre for families across Telangana and Andhra Pradesh.
Nothing on this page is a treatment instruction. GVHD treatment is chosen and adjusted by the transplant centre that performed the graft, on your grade and your organ involvement. Deliberately, no medicine is named here.
If symptoms appear
What Should You Do If You Notice GVHD Symptoms?
Report them the same day to the transplant centre that performed your transplant. Do not treat diarrhoea, a spreading rash or yellowing eyes at home. Do not stop or reduce your immune-suppressing medicines on your own. If you cannot reach the transplant team and symptoms are worsening, go to the nearest emergency department now.
- Call the transplant centre first, not a general clinic — they hold your graft details, your medicine list and your GVHD grade. Anyone treating you without those is guessing.
- Never stop immune-suppressing medicines on your own — halving a dose because you feel better is one of the commonest triggers for GVHD flaring back.
- Write down the date the symptom started — timing is what separates the early pattern from the long-lasting one, and what helps separate GVHD from an infection. A date is more useful than a description.
- Do not manage bowel symptoms at home — watery diarrhoea after a donor transplant is not treated as ordinary loose motion. Call the same day. If there is blood, or you cannot keep fluids down, go to the emergency department now.
- Tell every doctor you see that you have had a donor transplant — your dentist, your eye doctor and any emergency doctor included. It changes what they look for and what they can safely prescribe.
- Use our helpline if you are stuck — if you are in Telangana or Andhra Pradesh and cannot reach your transplant centre, call 1800 202 8726 and we will help you get to the right team.
Survivorship
What Does Long-Lasting GVHD Mean for a Young Survivor?
Chronic graft-versus-host disease is a long-term condition, not an episode that finishes. It can affect the eyes, mouth, skin, joints, gut, genitals and lungs, and it is managed over years rather than weeks. For young patients with decades of survivorship ahead, it is often the single biggest influence on daily life after transplant.
- It is a survivorship condition, not a complication that ends — follow-up continues for years, and treatment intensity moves up and down rather than simply stopping.
- Work, study and fertility all come into it — dry eyes, joint stiffness and fatigue shape what a working day looks like. Fertility, contraception and pregnancy planning after a transplant are separate conversations, and they belong at the start rather than years later.
- Eyes, mouth, skin and lungs need their own specialists — an ophthalmologist, a dentist and sometimes a chest physician sit alongside the transplant centre. Chronic GVHD is followed jointly, not by one doctor.
- Infection risk stays higher while treatment continues — vaccination after a transplant is rebuilt from scratch and timed by the transplant centre. Do not assume childhood vaccinations still count.
- Cost is part of the plan, and it should be in writing — allogeneic transplant and CAR-T are among the most expensive treatments in Indian oncology, and long-term GVHD care adds to that. Any figure you are quoted comes from the centre performing the procedure, and it is indicative only, as of August 2026. Ask what is not included.
One thing worth understanding. The donor immune activity that causes GVHD is related to the donor immune activity directed against the cancer itself — transplant teams call this the graft-versus-tumour effect. That is why the aim is usually to bring GVHD under control rather than switch the donor immune system off entirely. It is a balance your transplant centre manages deliberately, and it is a fair thing to ask them to explain.
Next step
Ask the Questions You Have Been Saving Up
Whether a transplant is even on the table, what GVHD would mean for you, and what happens where — brought together in one conversation, with your reports in front of us.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Graft-Versus-Host Disease: Your Questions Answered
What is graft-versus-host disease?
Graft-versus-host disease, or GVHD, is a reaction in which immune cells from a donor recognise your body as foreign and attack it. It happens after an allogeneic stem cell transplant, which uses stem cells from another person. It does not happen after an autologous transplant, which uses your own cells. The skin, the gut and the liver are affected most often, and the eyes, mouth, joints and lungs can be involved in the longer-lasting form. GVHD is not an infection, and it is not a side effect of chemotherapy. It is graded by severity, and the grade decides how it is treated.
Which organs does graft-versus-host disease affect?
Skin, the gastrointestinal tract and the liver are the three organs affected most often in the early form. Skin is usually first, with a red rash that often starts on the palms, soles, ears or upper back. Gut involvement shows as watery diarrhoea, cramping, nausea and loss of appetite. Liver involvement shows as yellowing of the eyes or skin, dark urine, or abnormal liver blood tests before you feel unwell. The longer-lasting form can also involve the eyes, the mouth, the joints and connective tissue, the genitals and the lungs. Lung involvement is easy to miss because it starts as gradual breathlessness.
How is graft-versus-host disease managed?
It is managed by the transplant centre, in three parts. First, prevention: the donor is matched as closely as possible and preventive immune-suppressing medicines are started around the time of the transplant. Second, early recognition: you are taught which symptoms to report, and you report them the same day rather than waiting for a scheduled visit. Third, treatment: limited skin disease may be treated locally, while more extensive disease is treated with steroids, and further immune-suppressing medicines are added if steroids alone are not enough. Infection prevention and long-term follow-up run alongside treatment, because suppressing the immune system raises infection risk.
Is graft-versus-host disease the same as an immunotherapy side effect?
No. They are different conditions with different causes, and confusing them is common. GVHD is caused by a donor's immune cells attacking your tissues after an allogeneic stem cell transplant. An immune-related side effect of checkpoint-inhibitor immunotherapy is caused by your own immune cells, released from their normal brakes by the drug, with no donor involved. The symptoms can look similar, particularly rash, diarrhoea and liver changes. The cause, the setting, the monitoring schedule and the team leading the care are all different. If your discharge summary uses one term while your treatment history points to the other, ask for it to be corrected in writing.
Can you get GVHD after CAR-T cell therapy or after your own stem cells?
Classical graft-versus-host disease needs immune cells from another person, so it is not expected after an autologous transplant, which uses your own stem cells. CAR-T cell therapy in India currently uses cells collected from the patient and re-engineered, so GVHD is not its typical complication either. CAR-T has its own distinct reactions, including cytokine release syndrome and neurological effects, which are monitored differently. CION does not perform allogeneic stem cell transplant and does not provide CAR-T or any other cell therapy. Both are referred to designated transplant centres, and we stay involved in the follow-up.
When does GVHD start, and how long does it last?
The early form usually appears within the first weeks to about three months after an allogeneic transplant, and it can come on quickly. The longer-lasting form usually appears from around three months onward, sometimes much later, and it develops slowly. The older rule that day 100 divides the two has been replaced. Transplant centres now classify GVHD by what it looks like rather than by the calendar, following the NIH consensus criteria. Some people have features of both patterns together. The longer-lasting form is managed over years rather than weeks, and follow-up continues for as long as it is active.